hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06279624 id: NRCT9-4 briefTitle: Effectiveness of the PCV13 in Older Thai Adults overallStatus: NOT_YET_RECRUITING date: 2024-02 date: 2025-03 date: 2025-06 date: 2024-02-28 date: 2024-02-29 name: Mahidol University class: OTHER name: National Research Council of Thailand briefSummary: This is the matched 1:2 case-control study, prospectively collect case and control who are diagnosed with pneumococcal or non-pneumococcal community acquired pneumonia (CAP), accordingly from November 2023 through October 2024. The investigators define a CASE as a person aged ≥60 years due to pneumococcal confirmed CAP either in-patients or out-patients by doctor in charge. While a CONTROL is defined as a person aged ≥60 years due to non-pneumococcal confirmed CAP either in-patients or out-patients by doctor in charge.
Researcher will compare the effectiveness of PCV13 to prevent all typed, vaccine typed and non-vaccine typed pneumococcal pneumonia. conditions: Community-acquired Pneumonia studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: OTHER count: 840 type: ESTIMATED measure: Vaccine effectiveness of PCV13 on all types of pneumococcal CAP measure: Vaccine effectiveness of PCV13 on PCV13 (vaccine typed) and non-PCV13 (non-vaccine typed) pneumococcal CAP sex: ALL minimumAge: 60 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06279611 id: LY007C1101 briefTitle: An Evaluation of LY007 Cell Injection for r/r B-NHL acronym: r/r B-NHL overallStatus: RECRUITING date: 2021-12-25 date: 2024-08-31 date: 2026-05-31 date: 2024-02-28 date: 2024-02-28 name: Shanghai Longyao Biotechnology Inc., Ltd. class: OTHER name: The First Affiliated Hospital with Nanjing Medical University name: Ruijin Hospital briefSummary: An evaluation of LY007 cell injection for recurrent/refractory CD20 was positive Tolerability, safety, and efficacy of B-cell non-Hodgkin lymphoma in open, single-arm Phsea I Clinical research conditions: B-NHL studyType: INTERVENTIONAL phases: PHASE1 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 18 type: ESTIMATED name: LY007 measure: Maximum tolerated dose or clinically recommended dose measure: Dose limiting toxicity measure: Adverse Events , Serious Adverse Events , Adverse Events of Particular Concern measure: PK aspect measure: PK aspect measure: PD aspect measure: therapeutic effect measure: Anti LY007 antibody measure: The titer of human anti mouse antibody measure: Exploratory study endpoint sex: ALL minimumAge: 18 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Ruijin hospital status: RECRUITING city: Shanghai state: Shanghai country: China name: zhao weili, MD role: CONTACT phone: 13512112076 phoneExt: 610707 email: zwl_trial@163.com name: yan zixun, MD role: CONTACT phone: +8613482056727 phoneExt: 610707 email: yanzixun125@163.com lat: 31.22222 lon: 121.45806 hasResults: False
nctId: NCT06279598 id: UniversityGroningen briefTitle: PT-STRESS Study: Predicting Treatment Success and Dealing With Non-response in the Treatment of PTSD acronym: PT-STRESS overallStatus: RECRUITING date: 2024-01-01 date: 2031-05-20 date: 2032-08-31 date: 2024-02-28 date: 2024-02-28 name: University of Groningen class: OTHER name: Dimence briefSummary: The aim of this study is to increase understanding of the effectiveness and efficiency of psychological treatment for adult patients with posttraumatic stress disorder -PTSD- and to make it more personalized.
nctId: NCT06279585 id: ECA GVHD briefTitle: Physical Therapy in Patients Undergoing Allo-HSCT With cGVHD overallStatus: NOT_YET_RECRUITING date: 2024-03-01 date: 2024-12 date: 2025-09 date: 2024-02-28 date: 2024-02-28 name: University of Seville class: OTHER briefSummary: Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT) represents the only curative option for many patients diagnosed with various hematologic neoplasms. Procedure-related morbidity and mortality pose challenges to long-term outcomes and quality of life, especially among patients who develop chronic graft-versus-host disease (cGVHD). There is a gap in healthcare that comprehensively addresses the specific needs of these patients. Physical therapy as an adjuvant treatment, through therapeutic exercise involving muscle strength and cardiorespiratory endurance, has shown positive influences on health markers and serves as a strong medical ally in similar profiles. Although these strategies could be reproducible and potentially beneficial for cGVHD patients, research has been limited to date, with the role of physical therapy possibly underutilized in this field. Justification: Unaddressed medical gap with no rigorously scientific responses specific to cGVHD. Objectives: This project aims to conduct the first randomized clinical trial from a physical therapy perspective as an adjuvant treatment for patients undergoing alloHSCT diagnosed with cGVHD. conditions: Graft-versus-host-disease conditions: Graft Versus Host Disease, Chronic conditions: Stem Cell Transplant Complications conditions: Hematological Malignancy conditions: Hematologic Cancer studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: DOUBLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR count: 108 type: ESTIMATED name: Physical therapy measure: Health-related quality of life measure: Chronic Graft-Versus-Host Disease (cGVHD) symptom burden measure: Muscular strength measure: Cardiorespiratory fitness measure: Functional status measure: Distress measure: Mood measure: Anxiety measure: Biological markers measure: Responses to medical treatment sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University of Seville; Manuel Siurot Avenue, no number city: Seville zip: 41013 country: Spain name: Raquel P Aguilar, Ph.D.cand. role: CONTACT phone: 955 013 260 phoneExt: 34 email: raquelijorml@gmail.com name: José Antonio P Simón, PhD role: CONTACT phone: 955 013 260 phoneExt: 34 email: josea.perez.simon.sspa@juntadeandalucia.es lat: 37.38283 lon: -5.97317 hasResults: False
nctId: NCT06279572 id: 20-011624 id: NCI-2022-09618 type: REGISTRY domain: CTRP (Clinical Trial Reporting Program) id: 20-011624 type: OTHER domain: Mayo Clinic Institutional Review Board briefTitle: Immune Profile of Acute Myeloid Leukemia Patients Receiving Azacitidine Plus Venetoclax Induction Chemotherapy overallStatus: RECRUITING date: 2021-04-22 date: 2025-12-31 date: 2026-12-31 date: 2024-02-28 date: 2024-02-28 name: Mayo Clinic class: OTHER briefSummary: This study investigates the immune profile of patients receiving treatment with venetoclax plus azacitidine for acute myeloid leukemia (AML). Studying the information gathered from the immune profile from blood and bone marrow samples may help researchers understand the associated responses to the treatment of patients undergoing therapy of venetoclax plus azacitidine and create future immune based treatment approaches. conditions: Acute Myeloid Leukemia studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 80 type: ESTIMATED name: Biospecimen Collection name: Bone Marrow Aspirate name: Electronic Health Record Review measure: Immune profile of treatment naive acute myeloid leukemia (AML) patients receiving azacitidine plus venetoclax chemotherapy sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Mayo Clinic in Arizona status: NOT_YET_RECRUITING city: Scottsdale state: Arizona zip: 85259 country: United States name: Clinical Trials Referral Office role: CONTACT phone: 855-776-0015 email: mayocliniccancerstudies@mayo.edu name: Cecilia Y. Arana Yi, M.D. role: PRINCIPAL_INVESTIGATOR lat: 33.50921 lon: -111.89903 facility: Mayo Clinic in Florida status: RECRUITING city: Jacksonville state: Florida zip: 32224-9980 country: United States name: Clinical Trials Referral Office role: CONTACT phone: 855-776-0015 email: mayocliniccancerstudies@mayo.edu name: Talha Badar, M.D. role: PRINCIPAL_INVESTIGATOR lat: 30.33218 lon: -81.65565 facility: Mayo Clinic in Rochester status: NOT_YET_RECRUITING city: Rochester state: Minnesota zip: 55905 country: United States name: Clinical Trials Referral Office role: CONTACT phone: 855-776-0015 email: mayocliniccancerstudies@mayo.edu name: Mithun V. Shah, M.D., Ph.D. role: PRINCIPAL_INVESTIGATOR lat: 44.02163 lon: -92.4699 hasResults: False
nctId: NCT06279559 id: MTinHRP_v1_10/01/2023 briefTitle: Music Therapy and High-risk Pregnancy overallStatus: RECRUITING date: 2023-06-01 date: 2024-12-01 date: 2024-12-01 date: 2024-02-28 date: 2024-02-28 name: Istituto Giannina Gaslini class: OTHER briefSummary: The objective of this clinical trial is to assess the impact of a music therapy intervention on reactive psychological components related to the risk of preterm birth in hospitalized pregnant women. The primary inquiries it seeks to address are:
Upon signing the informed consent, all three groups will be required to complete five self-report questionnaires assessing perceived positive and negative feelings, depressive symptoms, state anxiety and trait anxiety, perceived stress, and the mother-fetus attachment bond. Subsequently, the clinical experimental group will undergo ten online music therapy sessions, while the clinical control group will receive routine ward care. Following the music therapy sessions, both clinical groups will reassess the aforementioned measures. The non-clinical control group will complete the same self-report questionnaires with the same timing as the clinical groups. All three groups will be contacted three months after childbirth to complete a self-report questionnaire evaluating the postnatal attachment bond.
Researchers will compare the outcomes of the two clinical groups to address the first two research questions, while the comparison between the clinical control group and the non-clinical control group outcomes will be employed to answer the third research question. conditions: High Risk Pregnancy studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 72 type: ESTIMATED name: Music-therapy measure: Depressive symptoms measure: State anxiety and trait anxiety measure: Perceived stress measure: Perceived positive and negative feelings measure: Mother-fetus attachment bond measure: Mother-child attachment bond sex: FEMALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Istituto Giannina Gaslini status: RECRUITING city: Genova zip: 16147 country: Italy name: Cristina Venturino role: CONTACT phone: 010 5636.2346 email: cristinaventurino@gaslini.org lat: 44.40478 lon: 8.94438 hasResults: False
nctId: NCT06279546 id: IECED-12345 briefTitle: Artificial Intelligence vs Endoscopist Identification in EUS Normal Anatomy overallStatus: COMPLETED date: 2023-05-01 date: 2023-10-01 date: 2024-01-26 date: 2024-02-28 date: 2024-02-28 name: Instituto Ecuatoriano de Enfermedades Digestivas class: OTHER name: The Methodist Hospital Research Institute name: Baylor Saint Luke's Medical Center name: Beth Israel Deaconess Medical Center name: Barra Life Medical Center, Brazil name: Hospital Clinico Universitario de Santiago name: Universitair Ziekenhuis Brussel name: Hospital Civil de Morelia, Michoacan name: ELIAS Emergency University Hospital name: Larkin Community Hospital name: Carol Davila University of Medicine and Pharmacy name: mdconsgroup, Guayaquil, Ecuador briefSummary: Endoscopic ultrasound (EUS) visual impression is operator-dependant and can hinder diagnostic accuracy, especially in less experienced endoscopists. The implementation of artificial intelligence can potentially mitigate operator dependency and interpretation variability, helping or improving the overall accuracy.
The investigators therefore aim to compare diagnostic accuracy between artificial intelligence (AI)-based model and the endoscopists when identifying normal anatomical structures in EUS-procedures. conditions: Gastrointestinal Diseases studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: CROSS_SECTIONAL count: 30 type: ACTUAL name: Detection of structures measure: Diagnostic accuracy measure: Interobserver agreement sex: ALL minimumAge: 18 Years maximumAge: 99 Years stdAges: ADULT stdAges: OLDER_ADULT facility: IECED city: Guayaquil state: Guayas zip: 090505 country: Ecuador lat: -2.20584 lon: -79.90795 hasResults: False
nctId: NCT06279533 id: LV232-02 briefTitle: Safety and Pharmacokinetics Study of Multiple Ascending Doses and Food Effect of LV232 Capsules overallStatus: RECRUITING date: 2024-02-27 date: 2024-07 date: 2024-07 date: 2024-02-28 date: 2024-04-24 name: Vigonvita Life Sciences class: INDUSTRY briefSummary: This study is divided into two parts: the safety, tolerability, pharmacokinetic profiles of LV232 capsules after multiple ascending doses (hereinafter referred to as "PK characteristics of multiple ascending doses study ") and food effect study (hereinafter referred to as "FE study"). A total of 48 subjects are planned to be enrolled. The two parts of the study can be carried out simultaneously, and there is no order requirement. conditions: Healthy Subjects studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: PK characteristics of multiple ascending doses study is parallel design, and FE study is crossover design primaryPurpose: TREATMENT masking: TRIPLE maskingDescription: PK characteristics of multiple ascending doses study is double-blinded, placebo-controlled design, and FE study is open-label design whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR count: 48 type: ESTIMATED name: LV232/Placebo name: LV232 measure: Tmax measure: Cmax measure: T1/2 measure: AUC0-t measure: AUC0-24h measure: AUC0-∞ measure: Number of participants with treatment emergent treatment-related adverse event(s) measure: Laboratory test measure: Vital signs measure: Number of participants with ECG findings of potential clinical importance sex: ALL minimumAge: 18 Years maximumAge: 45 Years stdAges: ADULT facility: Shanghai Xuhui Central Hospital status: RECRUITING city: Shanghai country: China name: Chen Yu role: CONTACT lat: 31.22222 lon: 121.45806 hasResults: False
nctId: NCT06279520 id: 2023-08-003 briefTitle: Driving Ability Evaluation System to Improve the Conditional Driving License System: Safety and Feasibility Study. overallStatus: RECRUITING date: 2024-02-19 date: 2024-12-31 date: 2024-12-31 date: 2024-02-28 date: 2024-02-28 name: Seoul National University Hospital class: OTHER briefSummary: The primary objective of this study is to verify the safety and validity of a VR driving simulator developed for evaluating the driving abilities in healthy adults.
This study also aims to establish indicators in VR driving simulator to evaluate high-risk group for driving, such as cognitive and physical abilities. Therefore, this study aims to measure the physical driving function and cognitive function of healthy drivers. to identify the correlation between their outcomes and the VR driving simulator's result conditions: Automobile Driving studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: SCREENING masking: NONE count: 100 type: ESTIMATED name: VR Driving Simulator name: Computerized Neurocognitive Function Test name: Driver Test Station name: On-road field driving Test measure: Feasibility of VR driving simulator measure: Driving performance in simulator, measured by driving errors sex: ALL minimumAge: 19 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Seoul National University Hospital status: RECRUITING city: Seoul country: Korea, Republic of name: Ja-Ho Leigh, M.D. Msc. role: CONTACT email: mazican@gmail.com lat: 37.566 lon: 126.9784 hasResults: False
nctId: NCT06279507 id: PMK-00007 briefTitle: Efficacy of Hyaluronic Acid Injection in Knee Osteoarthritis overallStatus: RECRUITING date: 2024-02-10 date: 2025-01-31 date: 2025-06-30 date: 2024-02-28 date: 2024-02-28 name: Phramongkutklao College of Medicine and Hospital class: OTHER name: Chulalongkorn University name: Khon Kaen University name: Police General Hospital briefSummary: The aim of this clinical trial study is to compare the efficacy of Hyaluronic injection in patients with symptomatic knee osteoarthritis. The main questions it aims to answer are:
Researchers will compare the Hyaluronic acid with normal saline injection to see if the former show superior effect in terms of pain, joint stiffness, function, as well as health-related quality of life comparing with placebo. conditions: Knee Osteoarthritis conditions: Pain, Joint conditions: Stiffness of Knee, Not Elsewhere Classified conditions: Quality of Life studyType: INTERVENTIONAL phases: PHASE4 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: The participants would be allocated into one treatment group;
* Placebo group : Normal saline primaryPurpose: TREATMENT masking: QUADRUPLE maskingDescription: Participants will not know what treatment they receive. Co-investigators will not know what the participants are injected. Outcome assessor will not know which treatment participant receive. whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 176 type: ESTIMATED name: Sodium Hyaluronate name: Normal Saline name: Triamcinolone Acetonide 10mg/mL measure: Pain outcome measurement measure: Joint stiffness and function measurement measure: Overall symptom assessment measure: Knee performance evaluation measure: Quality of life assessment sex: ALL minimumAge: 50 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Phramongkutklao Hospital status: RECRUITING city: Bangkok zip: 10400 country: Thailand name: Suthee Panichkul role: CONTACT phone: 6623547600 phoneExt: 93681 email: suthee99@yahoo.com lat: 13.75398 lon: 100.50144 hasResults: False
nctId: NCT06279494 id: Sirolimus for GVHD prophylaxis briefTitle: Sirolimus+Abatacept+Mycophenolate Mofetil for Prophylaxis of aGVHD in Patients Receiving Haplo-HSCT Who Are Intolerant to Calcineurin Inhibitors overallStatus: NOT_YET_RECRUITING date: 2024-03 date: 2024-06 date: 2025-03 date: 2024-02-28 date: 2024-03-21 name: Peking University People's Hospital class: OTHER briefSummary: Graft-versus-host disease (GVHD) is an important complication after transplantation, with an incidence of 40-60%, which can increase non-relapse mortality if poorly controlled. At present, the standard prophylaxis for GVHD is cyclosporine combined with methotrexate. However, calcineurin inhibitors (CNI) can cause some vital side effects, which are not tolerated by some patients. Therefore, this study aims to explore the safety and efficacy of Sirolimus in combination with Abatacept and Mycophenolate Mofetil for the prophylaxis of GVHD in patients with haplo-HSCT who are intolerant to calcineurin inhibitors. conditions: Acute Leukemia conditions: Myelodysplastic Syndromes conditions: Severe Aplastic Anemia studyType: INTERVENTIONAL phases: PHASE1 phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: PREVENTION masking: NONE count: 6 type: ESTIMATED name: Sirolimus name: Abatacept name: MMF name: ATG measure: Incidence of Grade 2-4 aGVHD within 100 days post transplantation measure: Incidence of chronic GVHD (cGVHD) within 1 year post transplantation measure: Incidence of thrombotic microangiopathy within 1 year post transplantation measure: Cumulative incidence of relapse measure: Transplant-related mortality measure: Overall survival measure: Incidence of cytomegalovirus (CMV) and Epstein-Barr virus (EBV) sex: ALL minimumAge: 14 Years stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06279481 id: PUMCH-K2458 briefTitle: Effect of Virtual Reality (VR) on Pain Relieve During Colonoscopy overallStatus: RECRUITING date: 2024-03 date: 2024-12 date: 2024-12 date: 2024-02-28 date: 2024-02-28 name: Peking Union Medical College Hospital class: OTHER briefSummary: Purpose: To evaluate the effectiveness and safety of virtual reality (VR) technology in alleviating pain during colonoscopy.
Design and Methods: In the context of a single-centered, prospective, randomized controlled study, the pain levels experienced during colonoscopy are compared between the VR group and the control group. conditions: Pain conditions: Colonoscopy studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: a single-centered, prospective, randomized controlled study primaryPurpose: TREATMENT masking: NONE count: 98 type: ESTIMATED name: Nonpharmacological method measure: Comparison of Visual Analogue Scale Mean Scores by Groups measure: Comparison of State Trait Anxiety Inventory Mean Scores by Groups measure: Comparison of Vital Signs between Groups: Pulse Rate measure: Comparison of Vital Signs between Groups: Blood Pressure measure: Comparison of Vital Signs between Groups: Respiration Rate measure: Comparison of Vital Signs between Groups: Oxygen Saturation measure: Comparison of Patient Satisfaction of Colonoscopy between Groups measure: Comparison of Patient Willingness of Future Colonoscopy between Groups measure: Comparison of Adverse Effects in both groups sex: ALL minimumAge: 18 Years maximumAge: 50 Years stdAges: ADULT facility: Peking Union Medical College Hospital, Chinese Academy of Medical Sciences status: RECRUITING city: Beijing state: Beijing zip: 100010 country: China lat: 39.9075 lon: 116.39723 hasResults: False